stockrow
Friday 6 November 2026
Export CYTK’s income statement to Excel — free account
Cytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
53.84
1.71
−3.08%
Follow CYTK
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
86.68 | 76.78 | 166.28 | 76.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(53.50) | (55.86) | (70.40) | (70.20) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
89.80 | 80.04 | 166.01 | 78.29 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.50) | (16.17) | (20.22) | (15.51) | |
EV/FCF |
(14.78) | (15.43) | (19.34) | (15.07) | |
Quick Ratio |
4.45 | 4.14 | 6.56 | 3.29 | |
Current Ratio |
4.53 | 4.21 | 6.66 | 3.36 | |
Net Debt/EBITDA |
(1.57) | (1.91) | 0.11 | 5.85 | |
Debt/Assets |
81.23% | 91.29% | 59.60% | 9.56% | |
Debt/Equity |
(1.75) | (1.41) | (6.61) | (0.54) | |
Asset Turnover |
0.06 | 0.08 | 0.04 | 0.07 | |
Operating CF/Net income |
0.78 | 0.71 | 0.80 | 0.65 | |
Capex/Depreciation |
(1.97) | (1.76) | (1.19) | (0.19) | |
Interest Coverage |
(5.88) | (5.51) | (5.14) | — | |
Research and Development Expense of Revenue |
610.49% | 493.54% | 341.70% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
516.60% | 541.96% | 364.72% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
171.82% | 157.03% | 124.76% | 73.01% | |
Graham Net Nets |
(0.15) | (0.16) | (0.08) | (0.11) | |
Graham Number |
28.41 | 32.12 | 14.61 | 0.00 | |
Earnings Yield |
(10.28%) | (10.38%) | (8.48%) | (9.16%) | |
Free Cash Flow Yield |
(7.01%) | (6.76%) | (5.16%) | (6.76%) | |
Revenue per Share |
0.15 | 0.16 | 0.22 | 0.00 | |
Operating CF per Share |
(1.19) | (1.18) | (1.21) | 0.00 | |
Capex per Share |
(0.05) | (0.05) | (0.03) | 0.00 | |
Free Cash Flow per Share |
(1.23) | (1.23) | (1.24) | 0.00 | |
Cash per Share |
7.35 | 6.64 | 8.83 | 0.00 | |
Shareholders Equity per Share |
(5.49) | (6.71) | (1.31) | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(5.49) | (6.71) | (1.31) | 0.00 | |
Free Cash Flow |
(148.29) | (151.39) | (164.17) | (124.72) | |
Working Capital |
714.52 | 640.28 | 1,027.06 | 833.73 | |
Capital Expenditures |
(5.64) | (5.93) | (4.33) | (0.70) | |
Net Current Asset Value |
(1,167.19) | (1,260.58) | (889.55) | (958.80) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.32 | 0.31 | 0.15 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
17.21 | 4.42 | 16.42 | 17.85 | |
Average Payables |
21.35 | 19.33 | 18.37 | 24.02 | |
Average Assets |
1,413.11 | 1,268.76 | 1,575.09 | 1,630.67 | |
Average Common Equity |
(397.50) | (546.49) | (271.10) | (421.15) |
Columns are period end dates · fundamentals updated 4 Nov 2026